Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2001-09-18
2010-11-09
Myers, Carla (Department: 1634)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C435S091200, C536S023500, C536S024310, C536S024330
Reexamination Certificate
active
07829276
ABSTRACT:
Screening and diagnostic reagents, kits and methods for stomach or esophageal cancer are disclosed. Compounds, compositions and methods of treating patients with stomach or esophageal cancer and for imaging stomach or esophageal tumors in vivo are disclosed. Compositions and methods for delivering active compounds such as drugs, gene therapeutics and antisense compounds to stomach or esophageal cells are disclosed. Vaccines compositions and methods of for treating and preventing stomach or esophageal cancer are disclosed.
REFERENCES:
patent: 4022878 (1977-05-01), Gross
patent: 4329281 (1982-05-01), Christenson et al.
patent: 4526716 (1985-07-01), Stevens
patent: 4683195 (1987-07-01), Mullis et al.
patent: 4683202 (1987-07-01), Mullis
patent: 4736866 (1988-04-01), Leder et al.
patent: 4873191 (1989-10-01), Wagner et al.
patent: 4945050 (1990-07-01), Sanford et al.
patent: 4963263 (1990-10-01), Kauvar
patent: 4965188 (1990-10-01), Mullis et al.
patent: 5017487 (1991-05-01), Stunnenberg et al.
patent: 5037645 (1991-08-01), Strahilevitz
patent: 5075216 (1991-12-01), Innis et al.
patent: 5112606 (1992-05-01), Shiosaka et al.
patent: 5133866 (1992-07-01), Kauvar
patent: 5143854 (1992-09-01), Pirrung et al.
patent: 5217869 (1993-06-01), Kauvar
patent: 5221736 (1993-06-01), Coolidge et al.
patent: 5223409 (1993-06-01), Ladner et al.
patent: 5252743 (1993-10-01), Barrett et al.
patent: 5270170 (1993-12-01), Schatz et al.
patent: 5288514 (1994-02-01), Ellman
patent: 5324483 (1994-06-01), Cody et al.
patent: 5338665 (1994-08-01), Schatz et al.
patent: 5340474 (1994-08-01), Kauvar
patent: 5366862 (1994-11-01), Venton et al.
patent: 5384261 (1995-01-01), Winkler et al.
patent: 5395750 (1995-03-01), Dillon et al.
patent: 5405783 (1995-04-01), Pirrung et al.
patent: 5412087 (1995-05-01), McGall et al.
patent: 5420328 (1995-05-01), Campbell
patent: 5424186 (1995-06-01), Fodor et al.
patent: 5430138 (1995-07-01), Urdea et al.
patent: 5437977 (1995-08-01), Segev
patent: 5518888 (1996-05-01), Waldman
patent: 5597909 (1997-01-01), Urdea et al.
patent: 5601990 (1997-02-01), Waldman
patent: 5766888 (1998-06-01), Sobol et al.
patent: 5879656 (1999-03-01), Waldman
patent: 5962220 (1999-10-01), Waldman
patent: 6767704 (2004-07-01), Waldman et al.
patent: 2004/0224355 (2004-11-01), Waldman et al.
patent: WO 90/11092 (1990-10-01), None
patent: WO 95/11694 (1995-05-01), None
patent: WO 97/42220 (1997-11-01), None
patent: WO 97/42506 (1997-11-01), None
patent: WO 99/07726 (1999-02-01), None
Fava et al. Journal of Clinical Oncology. 2001. 19: 3951-3959.
Pearlman et al. Digestive Diseases and Sciences. 2000. 45: 298-305.
Vlems et al. Anticancer Research. 2003. 23: 179-186.
Alexander et al., “Oncogene alterations in rat colon tumors induced by N-methyl-N-nitrosourea,”Am J of the Medical Sciences(1992) 303(1):16-24.
Beck-Sickinger et al., “Neuropeptide Y: identification of the binding site,”Int J Peptide Protein Res(1990) 36(6):522.
Blond-Elguindi et al., “Affinity panning of a library of peptides displayed on bacteriophages reveals the binding specificity of BiP,”Cell(1993) 75:717-728.
Bold et al., “Experimental gene therapy of human colon cancer,”Surgery(1994) 116(2):189-195.
Carrithers et al., “Guanylyl cyclase C is a selective marker for metastatic colorectal tumors in human extraintestinal tissues.,”Proc Natl Acad Sci USA(1996) 93(25)14827-14832.
Carrithers et al., “Escherichia coliheat-stable enterotoxin receptors. A novel marker for colorectal tumors,”Dis Colon Rectum(1996) 39(2):171-181.
Carrithers et al, “Escherichia coliheat-stable toxin receptors in human colonic tumors,”Gastroenterology(1994) 107(6):1653-1661.
Ciardiello et al., “Inhibition of CRIPTO expression and tumorigenicity in human colon cancer cells by antisense RNA and oligodeoxynucleotides,”Oncogene(1994) 9(1):291-298.
Collins et al., “c-myc antisense oligonucleotides inhibit the colony-forming capacity of Colo 320 colonic carcinoma cells,”Journal of Clinical Investigation(1992) 89(5):1523-1527.
Cooney et al., “Site-specific oligonucleotide binding represses transcription of the human c-myc gene in vitro,”Science(1988) 241(4864):456-459.
Cull et al., “Screening for receptor ligands using large libraries of peptides linked to the C terminus of the lac repressor,”Proc Natl Acad Sci USA(1992) 89(5):1865-1869.
De Sauvage et al, “Primary structure and functional expression of the human receptor forEscherichia coliheat-stable enterotoxin,”J Biol Chem(1991) 266(27):17912-17918.
Francis et al., “Peptide vaccines based on enhanced immunogenicity of peptide epitopes presented with T-cell determinants or hepatitis B core protein,”Methods of Enzymol(1989) 178:659-676.
Francoeur et al., “Alternative splicing of natriuretic peptide A and B receptor transcripts in the rat brain,”Clinical and Experimental Pharmacology and Physiology(1995) 22(1):S172-S174.
Gallop et al., “Applications of combinatorial technologies to drug discovery. 1. Background and peptide combinatorial libraries,”J Medicinal Chemistry(1994) 37(9):1233-1251.
Gordon et al., “Applications of combinatorial technologies to drug discovery. 2. Combinatorial organic synthesis, library screening strategies, and future directions,”J Medicinal Chemistry(1994) 37(10):1385-401.
Hammer et al., “Promiscuous and allele-specific anchors in HLA-DR-binding peptides,”Cell(1993) 74(1):197-203.
Haralambidis et al., “The solid phase synthesis of oligonucleotides containing a 3′-peptide moiety,”Tetrahedron Lett(1987) 28(43):5199-5202.
Helene et al., “Specific regulation of gene expression by antisense, sense and antigene nucleic acids,”Biochem Biophys Acta(1990) 1049(2):99-125.
Kwok et al., “Calculation of radiation doses for nonuniformity distributed beta and gamma radionuclides in soft tissue,”Med Phys(1985) 12(4):405-412.
London et al., “Signal transduction pathways via guanylin and uroguanylin in stomach and intestine,”Am J of Physiology(1997) 273:G93-G105.
MacLean et al., “Immunization of breast cancer patients using a synthetic sialyl-Tn glycoconjugate plus Detox adjuvant,”Cancer Immunol Immunother(1993) 36(4):215-222.
Miller et al., “The induction of hapten-specific t cell tolerance by using hapten-modified lymphoid cells,”J Immunol(1976) 117(5:1):1591-1526.
Mizuno et al., “A variant form of the type C atrial natriuretic peptide receptor generated by alternative RNA splicing,”Journal of Biological Chemistry(1993) 268(7):5162-5167.
Nielsen et al., “Sequence-specific transcription arrest by peptide nucleic acid bound to the DNA template strand,”Gene(1994) 149(1):139-145.
Ohlmeyer et al., “Complex synthetic chemical libraries indexed with molecular tags,”Proc Natl Acad. Sci USA(1993) 90(23):10922-10926.
Ohyama et al., “Cloning and characterization of two forms of C-type natriuretic peptide receptor in rat brain,”Biochem&Biophys Research Comm(1992) 183(2):743-749.
Ostresh et al., “Libraries from libraries”: chemical transformation of combinatorial libraries to extend the range and repertoire of chemical diversity,Proc Natl Acad Sci USA(1994) 91(23):11138-11142.
Ruggeri et al., “Inhibition of platelet function with synthetic peptides designed to be high-affinity antagonists of fibrinogen binding to platelets,”Proc Natl Acad Sci USA(1986) 83(15):5708-5712.
Sad et al., “Bypass of carrier-induced epitope-specific suppression using a T-helper epitope,”Immunology(1992) 76(4)599-603.
Sepetov et al., “Library of libraries: approach to synthetic combinatorial library design and screening of “pharmacophore” motifs,”Proc Natl Acad Sci USA(1995) 92(12):5426-5430.
Singh et al., “Isolation and expression of a guanylate cyclase-coupled heat stable enterotoxin r
Barber Michael T.
Parkinson Scott J.
Pearlman Joshua M.
Prawer Scott
Schulz Stephanie
Myers Carla
Pepper Hamilton LLP
Thomas Jefferson University
LandOfFree
Methods of using CRCA-1 as a stomach and esophageal cancer... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of using CRCA-1 as a stomach and esophageal cancer..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of using CRCA-1 as a stomach and esophageal cancer... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4152877